The BASE-ACS randomized controlled trial

Study Design:

  • Multi-center, international, prospective, randomized, controlled trial
  • 14 sites
  • 827 patients
  • Primary Efficacy Endpoint: MACE at 12 months (cardiac death, MI or TLR)
  • Secondary Endoints : individual components of the primary endpoint, rate of thrombosis
  • Follow-up 18 & 60 months

Key Findings at 12 months follow ups:

The clinical trial met its primary endpoint of MACE non-inferiority at 12 month. The TiTAN2 TiNO coated bioactive stent achieved a low 9.6% MACE rate compared to 9.0% for Xience DES (p for non-inferiority = 0.001).